Recently, Li and colleagues reported that tumorigenic breast cancer cells expressing CD44+/CD24-/low have primary resistance to conventional chemotherapy and accordingly their proportion increases after chemotherapy. The gene discussed is CD24; the disease is breast carcinoma.